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Time series analysisRotavirus vaccines (RV) have decreased the infant morbidity and mortality in countries that included RV
in their national schedule. Rotavirus vaccination is recommended by the Spanish Society of Pediatrics;
however, Spain, as most countries in Europe, has authorized commercialization but not included RV in
its national vaccination program. We assessed the impact of RV on the rotavirus hospitalization rate
through an interrupted time series analysis. There was a 46.8% (95% CI: 29.3–60.2) decrease on the rota-
virus hospitalizations rate in the study region after RV commercialization in 2006. Currently there is lim-
ited evidence about the impact of RV in Europe, especially among countries not offering systematic
vaccination in their national schedule. Documentation of RV coverage, effectiveness and impact is
urgently needed in these countries.
 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Two rotavirus vaccines, Rotarix (GlaxoSmithKline, Rixensart,
Belgium) and RotaTeq (Merck and Co, Sanofi Pasteur MSD, Lyon,
France), are licensed since 2006 [1]. Several countries have
included rotavirus vaccines in their routine vaccination programs,
and high impact has been documented worldwide [2–6].
In Europe, 12 countries have introduced the rotavirus in their
national immunization programs [7]. The rest of the European
countries have commercialized rotavirus vaccines, but vaccines
have not been integrated in the routine schedules. This is the case
for Spain, where the vaccine is recommended by the Spanish Asso-
ciation of Paediatrics but not included in the national immuniza-
tion program [8], therefore vaccine needs to be purchased by
caregivers. Since 2010, only RotaTeq is available in the Spanish
market.
Estimates of the impact of the rotavirus vaccine are mainly
coming from countries including rotavirus as part of the national
vaccination program [9]. Here, we present an interrupted time
series analysis to describe the impact of the rotavirus vaccinecommercialization in an area of Spain that has maintained stable
surveillance of rotavirus diseases since 2000 [10].2. Methods
2.1. Study design and participants
We carried out an observational retrospective study. The study
period comprised 14 years from 2000 to 2013. The target popula-
tion was children under 5 years of age admitted in the Valladolid
Clinical University Hospital (CUH). The CUH is the main tertiary
hospital of Castilla y Leon region (2.5 million population) and
serves a population around 250,000 inhabitants from Valladolid
Province, including 5% of children under five.2.2. Variables and sources of information
The main variable of interest was the number of admissions due
to rotavirus gastroenteritis (code IDC10-CM: 008.61). Secondary
variables of interest included the number of admissions due to
diarrhea (codes IDC10-CM: 001-009 and 558), the median age of
infection and the median duration of the hospitalization. These
four outcomes were obtained from the admission register of the
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was obtained from the National Institute of Statistics.
2.3. Statistical analysis
The primary outcome was the weekly rotavirus hospitalization
rate. Two periods were considered in the analysis: the pre-vaccine
commercialization period (January 2000–June 2006) and the post-
vaccine commercialization period (July 2006–December 2013).
First, a generalized linear model with robust Poisson distribu-
tion including trend, seasonality and epidemic weeks was fitted
to weekly counts of rotavirus cases in the pre-vaccine commercial-
ization period to forecast the number of cases in the post-vaccine
commercialization period. Epidemic weeks were defined by the
Farrington algorithm [11]. The population was included as a log-
offset. The relative reduction in the number of cases was estimated
by: (expected number of cases  observed number of cases)/ex-
pected number of cases per cent.
Second, an interrupted time series analysis (segmented general-
ized linearmodelwith robust Poisson distribution)was used to ana-
lyze changes in the trend of rotavirus hospitalizations after vaccine
commercialization. The population was included as a log-offset.
This model was adjusted by the pre-vaccine commercialization sec-
ular trend, seasonality and epidemic weeks. Stata 11.2 (StataCorp,
College Station TX) was used to perform the analysis.
As secondary outcomes, we described the median age of infec-
tion, the median duration of the stay and the crude mortality rate
in the two above mentioned periods.
3. Results
3.1. Incidence of rotavirus gastroenteritis
A total of 1652 hospitalization with gastroenteritis as a primary
diagnosis were registered during the study period in children
under the age of five. The incidence rate of gastroenteritis hospital-
izations was 11.0 per 1000 children-year during the study period.
A total of 592 rotavirus gastroenteritis hospitalizations were
registered during the study period in children under the age of five.
The incidence rate during the pre-vaccination period was 5.9 cases
per 1000 children-year and 2.7 during the post-vaccination period
(Table 1). The highest incidence rate was observed in children
under 12 months of age both in the pre and post-vaccination peri-
ods (16.6 and 7.5 per 1000-children respectively).
3.2. Interrupted time series analysis
We assessed the impact of RV on the number of rotavirus hos-
pitalizations through an interrupted time series analysis (Fig. 1).Table 1
Rotavirus gastroenteritis (RV-GE) hospitalization rate, gastroenteritis (GE) hospitalization r
and the in the pre and post-vaccine commercialization periods. Valladolid University Hos
Indicators Pre-vaccine period (2000–June 200
n Persons-year
GE hospitalization rate 1095 60,050
RV-GE hospitalization rate 352 60,050
<12 months 189 11,362
12–23 months 121 11,905
24–59 months 42 36,783
Mortality rateb 129 120,100
Median age of RV-GE hospitalization 352
Median stay of RV-GE hospitalization 352
a Rates are expressed in cases/deaths per 1000 per year, median age is express in mo
b Mortality rates are provided for the entire Valladolid province as desegregated coun
Hospital.We estimated a 46.8% (95% CI: 29.3–60.2) reduction in the number
of rotavirus cases comparing the expected with the observed num-
ber of cases for the post-vaccine commercialization period. In the
multivariate interrupted time series analysis, the change in the
trend was statistically significant after vaccine commercialization
(Table 2). Most of the reduction in the number of rotavirus cases
occurred since 2010 as a result of the decreasing trend and the
absence of epidemic season (Fig. 1).
3.3. Secondary outcomes: median age of infection, duration of the
hospitalization and mortality rates
The median age of infection was slightly higher in the post-
vaccine commercialization period (p = 0.02) (Table 1). The increase
occurred mainly in the 2010–2013 period (median age at hospital-
ization = 12.5 months). The median duration of the stay decreased
since 2004; this trend did not change significantly after vaccine
commercialization (p = 0.704).
The mortality rate in children under five was 1.1 per 1000
children-year in the pre-vaccine period and 0.7 in the post-
vaccine period. The variation was not significant after adjustment
by the pre-existing trend (p = 0.175).4. Discussion
The results presented here show a moderate impact of the rota-
virus commercialization in Spain on the number of admissions due
to rotavirus in the study region. The mortality rate in children
under five has remained stable after vaccine commercialization.
The reduction documented in our study is the result of the decreas-
ing trend in the post vaccine introduction period and a lower num-
ber of epidemic years. The decreasing trend was not affected by the
interruption of Rotatix commercialization in Spain in 2010. The
decrease in the hospitalization rate is lower than in other countries
that have introduced rotavirus vaccine in their national vaccination
program [2–6,9]. Rotavirus vaccination is recommended by the
Spanish Society of Pediatrics but it has to be purchased by the care-
givers, thus a key factor that can explain these differences is low
and heterogeneous distribution of the vaccine coverage in the
study region.
The main limitation of this study is that our results are only rep-
resentative of the study area and they should not be extrapolated
to other regions in Spain; although, similar findings have been doc-
umented in other areas of the country [12,13]. Nonetheless, the rel-
atively low geographical scale of our study represents some
advantages. First, the data collection system and study population
has remained stable over time without major variations in the
socio-economic composition and health seeking behavior, factors
that can influence hospitalization rates. Second, hospitalizationate, crude mortality rate, median age of infection and the median duration of the stay
pital, Spain. 2000–2013.
6) Post-vaccine period (July 2006–2013)
Estimatea n Persons-year Estimatea
18.2 557 89,840 6.2
5.9 240 89,840 2.7a
16.6 129 17,289 7.5
10.2 78 18,305 4.3
1.1 33 54,246 0.6
1.1 122 179,680 0.7
11.1 240 11.5
6.0 240 4.0
nths, and median stay is expressed in days.
ts of death were not available for the catchment area of the Valladolid University
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Fig. 1. Observed rotavirus hospitalization (IDC-9-CM-code: 008.61) rates per 10,000 children (under five)-year and expected hospitalization rates in the post-vaccine
commercialization period (August 2006–2013) including 95% confidence intervals (CI), Valladolid University Hospital, Spain. *The expected values were estimated using a
robust Poisson regression model that included a baseline trend and an annual cycle and epidemic years. We assume the proportion of epidemic years and the same
percentage of epidemic week in the post vaccine introduction period than in the pre vaccine introduction period in order to calculate the expected number of rotavirus cases.
Table 2
Segmented generalized linear model with robust Poisson distribution.
Variables IRRa (95% CI) p-Value
Secular trend 1.000 (0.999–1.000) 0.468
Annual cycle (sine curve) 1.746 (1.581–1.928) 0.000
Annual cycle (cosine curve) 2.129 (1.912–2.371) 0.000
Epidemic weeks 3.377 (2.987–3.818) 0.000
Change in level after vaccine commercialization 0.883 (0.723–1.077) 0.219
Change in the trend after vaccine commercialization 0.998 (0.997–0.999) 0.000
a IRR: weekly incidence risk ratio.
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[10,14,15], which allows better understanding in the season-to-
season variation and the influence of the epidemic years. This
has been mentioned as one of the major limitations in before-
after studies including short periods of time [9]. This is relevant
for impact studies as season-to-season variation can have a large
influence on the estimates considering that unexpected large
decreases in the hospitalization rates have described during speci-
fic years in countries were vaccine has not been used [16]. Third,
the long follow-up period after vaccine introduction, allows char-
acterizing how rates are reduced. Our study clearly shows how rel-
evant is the reduction of epidemic years in decreasing diseases
burden, especially in the last 4 years of the study period. Long
pre and post vaccine introduction period allow to eliminate con-
founding related with season-to-season variation or modifications
in the seasonal patterns associated with changes in the percentage
of children susceptible in the study population [17].
In relation with the modification of the percentage of children
susceptible, it is interesting to mention that the median age of
rotavirus hospitalization slightly increase after vaccine commer-
cialization in our time series. An effective vaccination in childrenbetween 6 and 14 weeks is expected to increase the age of infec-
tion as a result of the decreasing number of children susceptible
at early ages, as observed in other studies [5,6]. The slightly
increase in the age of infection is coherent with a moderate reduc-
tion in the proportion of children under five susceptible to rota-
virus infection, and is likely related with the low amplitude of
the rotavirus season in the last years of our time series.
The duration of the rotavirus hospitalizations has decreased in
the last years in the study area. This decreasing trend started
before the vaccine introduction and it is probably not linked with
the vaccination itself, but with the implementation of stricter cri-
teria for discharge. Stricter criteria for discharge reduce the dura-
tion of the stay and thus decrease the direct cost of rotavirus
infections. However, they could increase the indirect cost for the
parents. Cost-benefit estimates have been crucial in the decision
making process for rotavirus vaccine introduction [9,10]. Thus,
accurate and updated estimates of the key parameter for economic
evaluations are needed in order to better inform decision makers
[18].
Rotavirus vaccines can be purchased in European countries that
have not introduced the vaccine in the national programs. The
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Nutrition, the European Society for Paediatric Infectious Diseases
and the Spanish Society of Paediatrics recommend the use of rota-
virus vaccines [8]. Nonetheless, the little information available in
countries with rotavirus vaccine not included in the immunization
schedules has shown low vaccine coverage [19], as it is estimated
in the study area (40%) [Supplementary Appendix]. The low cov-
erage could explain the moderate impact described here. The high
cost of the current vaccines might discourage both caregivers to
purchase the vaccine and decision makers to include the vaccine
in the immunization schedules [8,20], especially since 2007 con-
sidering the current economic crisis. On the other hand, the reduc-
tion of the rotavirus hospitalization rates and absence large
epidemic peaks, have likely had a positive indirect effect for those
requiring medical attention at a time of the year where other sea-
sonal pathogens, like influenza, cause high attendance to emer-
gency services. The decrease in the number of hospitalization
due to rotavirus could reduce as well the risk for nosocomial out-
breaks in winter periods [21].
In conclusion, we documented a decrease on the rotavirus hos-
pitalizations rate in the study region after the vaccine commercial-
ization in 2006 despite the fact that rotavirus vaccine is not part of
the national immunization program in Spain. A better understand-
ing of the direct and indirect benefits of vaccine is required in Spain
and in other countries without national rotavirus immunization
programs. Vaccine coverage estimates and reason for not vaccina-
tion are urgently needed to identify population that might be suf-
fering the highest burden of disease and could serve to reconsider
vaccination policies in Europe.Funding discloser
No specific funding was obtained for this study.Authors contributions
Conceived and designed the study: All authors. Performed the
study: FJL APR JME. Analyzed the data: FJL JME. Wrote the first
draft of the manuscript: FJL JME. Contributed to the writing of
the manuscript: all authors. Agree with manuscript results and
conclusions: all authors.Conflict of interest
Authors declare no conflict of interest.Acknowledgments
The authors would like to express their gratitude to the staff of
the Clinical Records Service of the University Clinical Hospital of
Valladolid for the assistance provided in data collection and to
Anne-Laure Page form Epicentre (Paris, France) for the critical
review of this manuscript.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.trivac.2016.04.
005.References
[1] K. Soares-Weiser, H. Maclehose, H. Bergman, I. Ben-Aharon, S. Nagpal, E.
Goldberg, et al., Cochrane Database of Systematic Reviews, vol. 11, John Wiley
& Sons, Ltd., Chichester, UK, 1996, http://dx.doi.org/10.1002/14651858.
CD008521.pub3.
[2] G.M.I. Do Carmo, C. Yen, J. Cortes, A.A. Siqueira, W.K. de Oliveira, J.J. Cortez-
Escalante, et al., Decline in diarrhea mortality and admissions after routine
childhood rotavirus immunization in Brazil: a time-series analysis, PLoS Med.
8 (2011) e1001024, http://dx.doi.org/10.1371/journal.pmed.1001024.
[3] M.M. Patel, U.D. Parashar, Assessing the effectiveness and public health impact
of rotavirus vaccines after introduction in immunization programs, J. Infect.
Dis. 200 (Suppl) (2009) S291–S299, http://dx.doi.org/10.1086/605059.
[4] V. Richardson, J. Hernandez-Pichardo, M. Quintanar-Solares, M. Esparza-
Aguilar, B. Johnson, C.M. Gomez-Altamirano, et al., Effect of rotavirus
vaccination on death from childhood diarrhea in Mexico, N. Engl. J. Med. 362
(2010) 299–305, http://dx.doi.org/10.1056/NEJMoa0905211.
[5] M. Paulke-Korinek, M. Kundi, P. Rendi-Wagner, A. de Martin, G. Eder, B.
Schmidle-Loss, et al., Herd immunity after two years of the universal mass
vaccination program against rotavirus gastroenteritis in Austria, Vaccine 29
(2011) 2791–2796, http://dx.doi.org/10.1016/j.vaccine.2011.01.104.
[6] G. Hanquet, G. Ducoffre, A. Vergison, P. Neels, M. Sabbe, P. Van Damme, et al.,
Impact of rotavirus vaccination on laboratory confirmed cases in Belgium,
Vaccine 29 (2011) 4698–4703, http://dx.doi.org/10.1016/j.vaccine.2011.
04.098.
[7] Control EC for DP and Recommended Immunisations for Rotavirus Infection
n.d., 2015. <http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx>
(accessed April 18, 2015).
[8] D. Moreno-Pérez, F.J. Álvarez García, J. Arístegui Fernández, M.J. Cilleruelo
Ortega, J.M. Corretger Rauet, N. García Sánchez, et al., Calendario de
vacunaciones de la Asociación Española de Pediatría: recomendaciones 2015,
An Pediatría 82 (2015), http://dx.doi.org/10.1016/j.anpedi.2014.10.019. 44.e1–
44.e12.
[9] E. Karafillakis, S. Hassounah, C. Atchison, Effectiveness and impact of rotavirus
vaccines in Europe, 2006–2014, Vaccine 33 (2015) 2097–2107, http://dx.doi.
org/10.1016/j.vaccine.2015.03.016.
[10] L. Gerstel, M.P. Rodrigo, B. Adiego, F.J. Luquero, M.J. Revillo, F.J. Castillo,
A. Barrasa, M. Valenciano, Is Rotavirus contributing to an increase of diarrhoea
in a region of Spain? Epidemiol. Infect. 137 (7) (2009) 950–956.
[11] D.G. Enki, A. Noufaily, P.H. Garthwaite, N.J. Andrews, A. Charlett, C. Lane, et al.,
Automated biosurveillance data from England and Wales, 1991–2011, Emerg.
Infect. Dis. 19 (2013) 35–42, http://dx.doi.org/10.3201/eid1901.120493.
[12] M. Bouzón-Alejandro, L. Redondo-Collazo, J. Sánchez-Lastres, N. Martinón-
Torres, J. Martinón-Sánchez, F. Martinón-Torres, Prospective evaluation of
indirect costs due to acute rotavirus gastroenteritis in Spain: the ROTACOST
study, BMC Pediatr. 11 (2011) 81, http://dx.doi.org/10.1186/1471-2431-11-81.
[13] R. Gil-Prieto, A. Gonzalez-Escalada, A. Alvaro-Meca, L. Garcia-Garcia, M. San-
Martin, A. González-López, et al., Impact of non-routine rotavirus vaccination
on hospitalizations for diarrhoea and rotavirus infections in Spain, Vaccine 31
(2013) 5000–5004, http://dx.doi.org/10.1016/j.vaccine.2013.05.109.
[14] F.J. Luquero, C. Hernán García, J.M. Eiros Bouza, J. Castrodeza Sanz, E. Sánchez-
Padilla, F. Simón Soria, et al., Profile of paediatric admissions and emergencies
during an epidemic period of rotavirus in Valladolid [Spain]. Utility of a
predictive model, Gac. Sanit. 23 (2009) 58–61, http://dx.doi.org/10.1016/
j.gaceta.2008.03.004.
[15] F.J. Luquero Alcalde, J.M. Eiros Bouza, A.P. Rubio, M.R. Bachiller Luque, J.J.
Castrodeza Sanz, Ortiz. de Lejarazu, R. Leonardo, Gastroenteritis by rotavirus in
Spanish children. Analysis of the disease burden, Eur. J. Pediatr. 167 (2008)
549–555, http://dx.doi.org/10.1007/s00431-007-0550-8.
[16] S. Hahné, M. Hooiveld, H. Vennema, A. van Ginkel, H. de Melker, J. Wallinga,
et al., Exceptionally low rotavirus incidence in the Netherlands in 2013/14 in
the absence of rotavirus vaccination, Euro. Surveill. 19 (2014).
[17] V.E. Pitzer, C. Viboud, L. Simonsen, C. Steiner, C.A. Panozzo, W.J. Alonso, et al.,
Demographic variability, vaccination, and the spatiotemporal dynamics of
rotavirus epidemics, Science 325 (2009) 290–294, http://dx.doi.org/
10.1126/science.1172330.
[18] J. Álvarez Aldeán, J. Aristegui, J.L. López-Belmonte, M. Pedrós, J.G. Sicilia,
Economic and psychosocial impact of rotavirus infection in Spain: a literature
review, Vaccine 32 (2014) 3740–3751, http://dx.doi.org/10.1016/j.vaccine.
2014.04.058.
[19] U. Uhlig, K. Kostev, V. Schuster, H.H. Uhlig, Rotavirus vaccination in Germany,
Pediatr. Infect. Dis. J. 30 (2011) e244–e247, http://dx.doi.org/10.1097/
INF.0b013e31822d1408.
[20] A. Pérez-Rubio, F.J. Luquero, J.M. Eiros Bouza, J.J. Castrodeza Sanz, M.R.
Bachiller Luque, R.O. de Lejarazu, et al., Socio-economic modelling of rotavirus
vaccination in Castilla y Leon, Spain, Infez. Med. 19 (2011) 166–175.
[21] M. Zlamy, S. Kofler, D. Orth, R. Würzner, P. Heinz-Erian, A. Streng, et al., The
impact of rotavirus mass vaccination on hospitalization rates, nosocomial
rotavirus gastroenteritis and secondary blood stream infections, BMC Infect.
Dis. 13 (2013) 112, http://dx.doi.org/10.1186/1471-2334-13-112.
